Corticosteroid Dosing in Pediatric Acute Severe Ulcerative Colitis: A Propensity Score Analysis

Area of Science:

• Pediatric Gastroenterology
• Clinical Pharmacology
• Inflammatory Bowel Disease Research

Background:

• Acute severe colitis in children requires effective treatment with intravenous corticosteroids (IVCS).
• Determining optimal IVCS dosing is crucial for maximizing efficacy while minimizing potential side effects.
• Previous studies have not definitively established the ideal IVCS dosage for pediatric ulcerative colitis.

Purpose of the Study:

• To investigate the optimal dosing strategy for IVCS in pediatric patients with acute severe colitis.
• To utilize a robust statistical method on the largest available pediatric cohort to date.
• To compare outcomes associated with different IVCS dosage levels.

Main Methods:

• A retrospective analysis of 283 children treated with IVCS for ulcerative colitis over one year.
• Propensity score matching was employed to address confounding by indication, comparing high- and low-IVCS dose groups.
• Three distinct IVCS dosage cutoffs were analyzed: 1 mg·kg⁻¹·day⁻¹, 1.25 mg·kg⁻¹·day⁻¹, and 2 mg·kg⁻¹·day⁻¹.

Main Results:

• No significant differences in clinical outcomes were observed between lower IVCS dosage groups (up to 1.25 mg·kg⁻¹·day⁻¹).
• Higher IVCS doses (2 mg·kg⁻¹·day⁻¹) showed a potential benefit that was not sustained in sensitivity analyses or regression models.
• Successful matching was confirmed by the absence of significant differences in 25 baseline variables across dosage cutoffs.

Conclusions:

• Current guidelines supporting IVCS doses up to 1 to 1.5 mg·kg⁻¹·day⁻¹ (max 40-60 mg/day) are supported by this study's findings.
• Doses exceeding 1.5 mg·kg⁻¹·day⁻¹ are not statistically justified for treating acute severe colitis in children.
• This research provides evidence-based recommendations for IVCS dosing in pediatric ulcerative colitis.